Such findings have now been translated into the CAR-T cell field, whereby siRNA targeting of ACAT1 in a mesothelin-expressing pancreatic carcinoma model reduced tumour volume, elevated IFNγ levels, and improved overall cancer targeting in vivo [62]. This evidence concerns the gene ACAT1 and neoplasm.